2
Orphan Designations
2 approved
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Presutti Laboratories, Inc. is a company with 2 orphan drug designations across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| amebiasis | Tindamax | Des.TrialAppr. |
| amebic dysentery | Tindamax | Des.TrialAppr. |
| amelia of lower limb | Tindamax | Des.TrialAppr. |
| giardiasis | Tindamax | Des.TrialAppr. |
| granulomatous amebic encephalitis | Tindamax | Des.TrialAppr. |
| primary amebic meningoencephalitis | Tindamax | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio